Rituximab vs. Cyclophosphamide induction therapy for patients with ANCA-associated vasculitis.

ABSTRACT:

Objectives

To evaluate the effectiveness and safety of rituximab (RTX) compared to cyclophosphamide (CYC) in inducing remission with ANCA-associated vasculitis (AAV).

Methods

This retrospective study included patients admitted to Renji Hospital from January 2017 to December 2023 who received induction treatment with either RTX or CYC. Effectiveness was evaluated by remission rate at month 6 (± 2 months), with additional subgroup analyses. Safety was assessed based on the occurrence of infections within 6 (± 2) months post-immunosuppression. Comparative analyses and logistic regression were performed using the Inverse Probability of Treatment Weighting (IPTW) method to bolster the reliability of the findings.

Results

A total of 293 patients were enrolled, with 124 trea

SUBMITTER: Wu W 

PROVIDER: S-EPMC12661734 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature